TN2017000385A1 - Use of substituted 2,3-dihydroimidaz0[1,2-c]quinazolines. - Google Patents
Use of substituted 2,3-dihydroimidaz0[1,2-c]quinazolines.Info
- Publication number
- TN2017000385A1 TN2017000385A1 TNP/2017/000385A TN2017000385A TN2017000385A1 TN 2017000385 A1 TN2017000385 A1 TN 2017000385A1 TN 2017000385 A TN2017000385 A TN 2017000385A TN 2017000385 A1 TN2017000385 A1 TN 2017000385A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compound
- pharmaceutical composition
- type
- line
- loss
- Prior art date
Links
- 150000003246 quinazolines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000013543 active substance Substances 0.000 abstract 5
- -1 quinazoline compound Chemical class 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 abstract 3
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 abstract 3
- 206010014733 Endometrial cancer Diseases 0.000 abstract 2
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 2
- 201000009273 Endometriosis Diseases 0.000 abstract 2
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 abstract 2
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 abstract 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 abstract 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 abstract 2
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 abstract 2
- 101001098116 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit gamma Proteins 0.000 abstract 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 abstract 2
- 101000595741 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 abstract 2
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 abstract 2
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 abstract 2
- 101000692672 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 4 Proteins 0.000 abstract 2
- 101000692678 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 5 Proteins 0.000 abstract 2
- 102100026177 Phosphatidylinositol 3-kinase regulatory subunit beta Human genes 0.000 abstract 2
- 102100037553 Phosphatidylinositol 3-kinase regulatory subunit gamma Human genes 0.000 abstract 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 abstract 2
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 abstract 2
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 abstract 2
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 abstract 2
- 102100026481 Phosphoinositide 3-kinase regulatory subunit 4 Human genes 0.000 abstract 2
- 102100026478 Phosphoinositide 3-kinase regulatory subunit 5 Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130547P | 2015-03-09 | 2015-03-09 | |
| PCT/EP2016/054728 WO2016142313A1 (en) | 2015-03-09 | 2016-03-07 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2017000385A1 true TN2017000385A1 (en) | 2019-01-16 |
Family
ID=55484986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2017/000385A TN2017000385A1 (en) | 2015-03-09 | 2016-03-07 | Use of substituted 2,3-dihydroimidaz0[1,2-c]quinazolines. |
Country Status (18)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| WO2014166820A1 (en) | 2013-04-08 | 2014-10-16 | Bayer Pharma Aktiengesllschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| US10406162B2 (en) | 2015-03-09 | 2019-09-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations |
| CN108884098B (zh) | 2016-03-08 | 2021-09-14 | 拜耳制药股份公司 | 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US11185549B2 (en) | 2017-06-28 | 2021-11-30 | Bayer Consumer Care Ag | Combination of a PI3K-inhibitor with an androgen receptor antagonist |
| CN111500587A (zh) * | 2020-04-15 | 2020-08-07 | 湖南省科域生物医药科技有限公司 | Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒 |
| EP4143569A4 (en) * | 2020-05-01 | 2024-05-29 | Mayo Foundation for Medical Education and Research | Methods and materials for treating endometrial cancer |
| WO2022140467A1 (en) * | 2020-12-21 | 2022-06-30 | Samson Pharma, Llc | Topical compositions and methods of treating skin diseases and conditions with such compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0615654A2 (pt) * | 2005-09-07 | 2011-05-24 | Serono Lab | inibidores da pi3k para o tratamento de endometriose |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| US20130184270A1 (en) * | 2010-04-16 | 2013-07-18 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| WO2014191938A1 (en) * | 2013-05-31 | 2014-12-04 | Novartis Ag | Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer |
-
2016
- 2016-03-07 MX MX2017011607A patent/MX2017011607A/es unknown
- 2016-03-07 JP JP2017548211A patent/JP2018512403A/ja not_active Withdrawn
- 2016-03-07 KR KR1020177027607A patent/KR20180013850A/ko not_active Withdrawn
- 2016-03-07 BR BR112017019190A patent/BR112017019190A2/pt not_active Application Discontinuation
- 2016-03-07 US US15/557,036 patent/US20180042929A1/en not_active Abandoned
- 2016-03-07 EA EA201791975A patent/EA201791975A1/ru unknown
- 2016-03-07 HK HK18110118.6A patent/HK1250645A1/zh unknown
- 2016-03-07 TN TNP/2017/000385A patent/TN2017000385A1/en unknown
- 2016-03-07 MA MA043840A patent/MA43840A/fr unknown
- 2016-03-07 AU AU2016231260A patent/AU2016231260A1/en not_active Abandoned
- 2016-03-07 SG SG11201707239WA patent/SG11201707239WA/en unknown
- 2016-03-07 CA CA2978807A patent/CA2978807A1/en not_active Abandoned
- 2016-03-07 CN CN201680022080.8A patent/CN107683138A/zh active Pending
- 2016-03-07 WO PCT/EP2016/054728 patent/WO2016142313A1/en not_active Ceased
- 2016-03-07 EP EP16708402.9A patent/EP3268005A1/en not_active Withdrawn
-
2017
- 2017-08-27 IL IL254168A patent/IL254168A0/en unknown
- 2017-09-08 PH PH12017501644A patent/PH12017501644A1/en unknown
- 2017-09-08 CL CL2017002284A patent/CL2017002284A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA43840A (fr) | 2018-11-21 |
| PH12017501644A1 (en) | 2018-03-12 |
| HK1250645A1 (zh) | 2019-01-11 |
| IL254168A0 (en) | 2017-10-31 |
| JP2018512403A (ja) | 2018-05-17 |
| BR112017019190A2 (pt) | 2018-04-24 |
| US20180042929A1 (en) | 2018-02-15 |
| CN107683138A (zh) | 2018-02-09 |
| CA2978807A1 (en) | 2016-09-15 |
| CL2017002284A1 (es) | 2018-05-18 |
| EA201791975A1 (ru) | 2018-03-30 |
| EP3268005A1 (en) | 2018-01-17 |
| AU2016231260A1 (en) | 2017-09-21 |
| KR20180013850A (ko) | 2018-02-07 |
| MX2017011607A (es) | 2018-04-10 |
| WO2016142313A1 (en) | 2016-09-15 |
| SG11201707239WA (en) | 2017-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2017000385A1 (en) | Use of substituted 2,3-dihydroimidaz0[1,2-c]quinazolines. | |
| PH12017501643A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| MY169532A (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| ES2993832T3 (en) | Methods of treatment with cyp3a4 substrate drugs | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| MX2018001268A (es) | Combinacion de antagonista de pd-1 con un inhibidor de egfr. | |
| MX378263B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| MA34903B1 (fr) | Derives de type azaindazole ou diazaindazole utilises comme medicaments | |
| SG10201906270VA (en) | Combination therapy comprising a b-raf inhibitor and a second inhibitor | |
| TN2013000237A1 (en) | Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor | |
| BR112017003186A2 (pt) | composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos | |
| ZA202304064B (en) | Quinoline cgas antagonist compounds | |
| AR082691A1 (es) | Terapia de combinacion, producto farmaceutico, kit y uso | |
| BR112015022846A2 (pt) | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo | |
| MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
| WO2011101634A3 (en) | Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist | |
| BR112018012626A2 (pt) | ccl20 como um preditor de resposta clínica a antagonistas de il23 | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| ZA201808562B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| BR112021017829A2 (pt) | Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer | |
| Shin et al. | Serum 25-hydroxyvitamin D levels correlate with EGFR mutational status in pulmonary adenocarcinoma | |
| MX2015011833A (es) | Kits y métodos para el tratamiento de cáncer con péptidos de gliadina. | |
| Mayor | MET inhibitors: translating from bench to bedside | |
| Choueiri | CABOZANTINIB AS FIRST-LINE THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WITH POOR OR INTERMEDIATE-RISK CHARACTERISTICS | |
| Shibamoto et al. | IMAX (Immunity-maximized) Cancer Therapy: Combination of Dendritic Cell-based Vaccine and Intensity Modulated Radiation |